First-in-class precision targeted approach for cancer therapy
Advancing Cancer Medicine
A new treatment platform compatible with other treatment modalities to improve patient outcomes and survival
Transforming the Lives of patients
We are for the patients, to provide them with new options to battle and cure the disease
Rakuten Aspyrian: Developing Precision Targeted Therapies Against Cancer
Rakuten Aspyrian, Inc., is a privately funded clinical stage biotechnology company developing oncologic drugs for the treatment of solid tumors. Established in 2011, this San Diego-based company holds the exclusive license to utilize photoimmunotherapy for the rapid, safe, and specific destruction of locoregional tumors in cancer patients.
Rakuten Aspyrian is currently sponsoring a multicenter clinical study for RM-1929 to treat patients with recurrent Head and Neck Cancer. For information about the trial and for enrollment considerations please visit our Clinical Trials Page.